WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
Ticker
Company
Performance Score
Market Cap
Revenue
EBITDA
Earnings
EPS
Revenue Growth Y/Y
Revenue Growth 5Y
Earnings Growth Y/Y
Earnings Growth 5Y
Earnings Date
FONR
FONAR CORP
$109.45M$102.42M$25.75M$12.16M$1.895.78%4.06%51.20%-8.83%2024-05-20
ICLR
ICON PLC
$25.55B$8.23B$1.62B$683.12M$8.305.29%25.44%32.80%6.18%
STRR
STAR EQUITY HOLDINGS INC
$14.26M$45.79M$26.87M$23.22M$1.61-19.88%-15.16%N/A34.19%2024-05-13
RVTY
REVVITY INC
$12.43B$2.75B$1.25B$693.09M$5.56-16.95%-0.20%23.28%20.93%2024-05-14
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$11.99B$4.13B$1.03B$474.62M$9.273.86%12.75%-3.13%14.45%2024-05-09
NEOG
NEOGEN CORP
$2.60B$929.24M$188.76M$1.57M$0.0228.93%17.63%-50.00%-49.27%
IDXX
IDEXX LABORATORIES INC
$39.69B$3.72B$1.24B$866.57M$10.438.57%10.59%24.17%18.31%
TMO
THERMO FISHER SCIENTIFIC INC
$218.49B$42.49B$11.37B$6.03B$15.65-3.00%11.52%1.36%14.62%2024-05-22
ENZ
ENZO BIOCHEM INC
$53.27M$12.81M$33.74M$32.57M$0.67N/A-32.08%N/AN/A2024-06-12
A
AGILENT TECHNOLOGIES INC
$40.87B$6.74B$1.69B$1.24B$4.22-2.81%6.19%-5.17%3.46%2024-05-29
QGEN
QIAGEN NV
$9.62B$1.94B$680.17M$336.94M$1.47-2.99%5.17%-3.36%10.88%2024-06-21
DGX
QUEST DIAGNOSTICS INC
$15.26B$9.29B$1.70B$846.00M$7.53-3.29%4.26%8.66%7.24%2024-05-16
SHC
SOTERA HEALTH CO
$3.12B$1.08B$426.24M$54.86M$0.199.05%N/AN/AN/A2024-05-23
DHR
DANAHER CORP
$183.97B$22.52B$7.54B$4.40B$5.96-9.58%6.32%-36.66%11.68%2024-05-07
MEDP
MEDPACE HOLDINGS INC
$12.16B$1.96B$405.89M$312.51M$10.1725.57%21.47%24.33%36.07%2024-05-17
WAT
WATERS CORP
$19.02B$2.96B$1.00B$642.23M$10.87-0.52%4.09%-7.88%7.11%2024-05-23
LH
LABORATORY CORP OF AMERICA HOLDINGS
$16.97B$12.30B$1.55B$433.10M$5.104.62%1.75%-54.34%-10.52%2024-05-14
MTD
METTLER TOLEDO INTERNATIONAL INC
$26.89B$3.79B$1.17B$788.78M$36.10-3.35%5.23%-6.93%12.17%2024-05-09
FLGT
FULGENT GENETICS INC
$643.37M$287.53M-$127.63M-$165.95M-$5.57-21.20%67.10%N/AN/A
SERA
SERA PROGNOSTICS INC
$351.82M$306.00k-$34.76M-$36.24M-$1.1614.18%N/AN/AN/A2024-05-08
CSTL
CASTLE BIOSCIENCES INC
$671.68M$250.73M-$17.87M-$30.80M-$1.1464.71%55.20%N/AN/A
PRE
PRENETICS GLOBAL LTD
$63.83M$21.74M-$55.20M-$62.72M-$5.5865.17%18.68%N/AN/A
IQV
IQVIA HOLDINGS INC
$40.70B$15.07B$3.27B$1.36B$7.423.97%7.43%30.86%43.25%
NTRA
NATERA INC
$11.71B$1.08B-$383.28M-$434.80M-$3.7831.99%33.26%N/AN/A2024-05-09
PSNL
PERSONALIS INC
$77.78M$73.48M-$94.95M-$108.30M-$2.2512.97%14.23%N/AN/A2024-05-08
PRPO
PRECIPIO INC
$8.30M$15.20M-$4.32M-$5.85M-$4.5161.46%39.62%N/AN/A2024-06-14
DRIO
DARIOHEALTH CORP
$46.22M$20.35M-$54.38M-$63.51M-$1.93-26.41%22.45%N/AN/A2024-05-09
OLK
OLINK HOLDING AB (PUBL)
$2.86B$169.60M-$20.05M-$31.60M-$0.2521.27%N/AN/AN/A2024-05-09
ACRS
ACLARIS THERAPEUTICS INC
$96.46M$31.25M-$87.99M-$88.48M-$1.275.03%38.41%N/AN/A2024-06-06
NEO
NEOGENOMICS INC
$1.95B$610.66M$1.33M-$84.23M-$0.6615.27%14.60%N/AN/A2024-05-23
DMTK
DERMTECH INC
$21.78M$15.30M-$95.04M-$100.89M-$3.095.36%44.33%N/AN/A2024-05-30
TWST
TWIST BIOSCIENCE CORP
$2.40B$277.49M-$155.32M-$192.14M-$3.3621.79%47.31%N/AN/A
STIM
NEURONETICS INC
$113.37M$71.35M-$22.76M-$30.19M-$1.059.42%6.22%N/AN/A2024-05-30
EXAS
EXACT SCIENCES CORP
$11.27B$2.50B$52.20M-$204.15M-$1.1319.93%40.63%N/AN/A2024-06-13
BGLC
BIONEXUS GENE LAB CORP
$10.67M$9.77M-$2.49M-$2.63M-$0.18-10.60%115.07%N/AN/A
RDNT
RADNET INC
$3.51B$1.62B$265.49M$3.04M$0.0513.05%10.64%-73.68%-40.49%2024-06-12
OCX
ONCOCYTE CORP
$22.01M$1.50M-$26.05M-$28.72M-$3.7556.89%N/AN/AN/A2024-06-21
BNR
BURNING ROCK BIOTECH LTD
$82.67M$74.33M-$71.63M-$90.41M-$0.88-6.20%20.19%N/AN/A2024-05-28
APDN
APPLIED DNA SCIENCES INC
$3.18M$9.00M-$5.89M-$7.29M-$11.00-53.31%16.79%N/AN/A2024-05-09
LAB
STANDARD BIOTOOLS INC
$728.20M$106.34M-$65.66M-$74.66M-$0.948.57%-1.20%N/AN/A2024-06-13
XGN
EXAGEN INC
$24.13M$52.55M-$18.21M-$23.69M-$1.3415.33%10.13%N/AN/A2024-06-10
XWEL
XWELL INC
$7.49M$30.11M-$24.16M-$27.74M-$6.64-46.18%-9.68%N/AN/A2024-05-13
GH
GUARDANT HEALTH INC
$2.30B$563.95M-$433.31M-$479.45M-$4.2825.45%44.14%N/AN/A2024-05-09
CDNA
CAREDX INC
$503.29M$280.32M-$182.19M-$190.28M-$3.54-12.89%29.63%N/AN/A2024-05-09
BDSX
BIODESIX INC
$135.72M$49.09M-$37.10M-$52.15M-$0.6428.46%19.16%N/AN/A2024-05-21
CHEK
CHECK-CAP LTD
$12.87M$0.00-$19.08M-$17.62M-$3.02N/AN/AN/AN/A2024-05-06
ME
23ANDME HOLDING CO
$242.42M$247.99M-$490.64M-$521.97M-$1.11-19.40%N/AN/AN/A2024-05-26
ULS
UL SOLUTIONS INC
N/A$2.68B$519.00M$260.00M$1.306.27%N/A-11.56%N/A
PRPH
PROPHASE LABS INC
$97.81M$44.38M-$14.83M-$16.78M-$0.98-63.81%27.59%N/AN/A2024-05-09
NDRA
ENDRA LIFE SCIENCES INC
$3.61M$0.00-$9.78M-$10.06M-$1.58N/A-100.00%N/AN/A2024-05-13
OPK
OPKO HEALTH INC
$906.09M$863.50M-$65.62M-$188.86M-$0.25-14.01%-2.70%N/AN/A2024-05-07
NOTV
INOTIV INC
$110.13M$585.17M$59.57M-$33.21M-$1.30-0.18%81.64%N/AN/A2024-05-10
AWH
ASPIRA WOMEN's HEALTH INC
$39.62M$9.15M-$16.50M-$16.69M-$1.8111.85%24.56%N/AN/A2024-05-13
MDXH
MDXHEALTH SA
$8.57M$75.33M-$21.40M-$39.90M-$13.7065.02%N/AN/AN/A2024-05-30
VNRX
VOLITIONRX LTD
$73.12M$775.30k-$33.68M-$35.32M-$0.50153.04%N/AN/AN/A2024-05-08
GENE
GENETIC TECHNOLOGIES LTD
$520.53k$5.55MN/A-$8.33M-$2.98-3.27%136.93%N/AN/A
ISPC
ISPECIMEN INC
$2.39M$9.93M-$9.02M-$11.10M-$1.23-4.56%N/AN/AN/A2024-05-07
MYGN
MYRIAD GENETICS INC
$1.75B$753.20M-$186.10M-$263.30M-$3.1811.03%-1.10%N/AN/A2024-05-07
BIAF
BIOAFFINITY TECHNOLOGIES INC
$24.07M$2.53M-$7.63M-$7.94M-$0.9152,627.44%N/AN/AN/A2024-05-13
ILMN
ILLUMINA INC
$18.79B$4.49B-$640.00M-$1.29B-$8.151.03%5.76%N/AN/A
PMD
PSYCHEMEDICS CORP
$14.64M$22.10M-$768.00k-$4.15M-$0.72-12.45%-12.33%N/AN/A2024-05-07
TRIB
TRINITY BIOTECH PLC
$13.81M$56.83M-$11.25M-$24.02M-$3.20-9.10%-10.15%N/AN/A
MYNZ
MAINZ BIOMED NV
$15.60M$895.48k-$24.62M-$26.30M-$1.6269.00%N/AN/AN/A2024-05-31
MMA
ALTA GLOBAL GROUP LTD
N/A$1.54M-$16.12M-$20.60M-$5.2663.35%N/AN/AN/A
CNTG
CENTOGENE NV
$12.22M$55.12M-$44.39M-$61.44M-$1.58N/AN/AN/AN/A2024-06-28
TTOO
T2 BIOSYSTEMS INC
$20.51M$7.19M-$42.53M-$50.08M-$19.19-67.75%-7.29%N/AN/A2024-05-06

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in May 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the top diagnostic & research stock with a Zen Score of 47, which is 20 points higher than the diagnostic & research industry average of 27. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 3.69% over the past year, overperforming other diagnostic & research stocks by 4 percentage points.

2. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the second best diagnostic & research stock with a Zen Score of 47, which is 20 points higher than the diagnostic & research industry average of 27. It passed 15 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock return 66.35% over the past year, overperforming other diagnostic & research stocks by 67 percentage points.

Icon has an average 1 year price target of $344.38, an upside of 11.44% from Icon's current stock price of $309.02.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Icon, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the third best diagnostic & research stock with a Zen Score of 46, which is 19 points higher than the diagnostic & research industry average of 27. It passed 18 out of 38 due diligence checks and has strong fundamentals. Star Equity Holdings has seen its stock return 37.4% over the past year, overperforming other diagnostic & research stocks by 38 percentage points.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 2.98%, which is 2 percentage points higher than the diagnostic & research industry average of 1.36%.

Qiagen Nv's dividend payout ratio of 87.2% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.1%, which is 1 percentage points higher than the diagnostic & research industry average of 1.36%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.2% indicates that its dividend yield is sustainable for the long-term.

3. Laboratory Of America Holdings (NYSE:LH)


Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.43%, which is the same as the diagnostic & research industry average of 1.36%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 56.5% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks up?

Diagnostic & research stocks were up 0.85% in the last day, and up 0.7% over the last week. Twist Bioscience was the among the top gainers in the diagnostics & research industry, gaining 28.74% yesterday.

Twist Bioscience shares are trading higher after the company reported better-than-expected Q2 financial results.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 52 points higher than the diagnostic & research industry average of 19. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 37.4% in the past year. It has overperformed other stocks in the diagnostic & research industry by 38 percentage points.

2. Enzo Biochem (NYSE:ENZ)


Enzo Biochem (NYSE:ENZ) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 52 points higher than the diagnostic & research industry average of 19. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -59.85% in the past year. It has underperformed other stocks in the diagnostic & research industry by -59 percentage points.

3. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 52 points higher than the diagnostic & research industry average of 19. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 3.69% in the past year. It has overperformed other stocks in the diagnostic & research industry by 4 percentage points.

Are diagnostic & research stocks a good buy now?

52.08% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 10.51% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 38.44x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.